Home > Insider Trading > Filing (0001104659-22-063844)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1297184	Amphastar Pharmaceuticals Inc.	AMPH	Pharmaceutical Preparations (2834)	330702205

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1611156	Z. Mary Luo	C/O Amphastar Pharmaceuticals, Inc. 11570 6Th Street Rancho Cucamonga CA 91730	Ceo & Chief Scientific Officer	Yes	Yes	Yes	No
1611157	Y. Jack Zhang	C/O Amphastar Pharmaceuticals, Inc. 11570 6Th Street Rancho Cucamonga CA 91730	Ceo & Chief Scientific Officer	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-05-20	10,650	$34.21	2,104,143	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,498,519	Indirect	See footnote
Common Stock	6,827,679	Indirect	See footnote
Common Stock	5,000	Indirect	See footnote

Footnotes

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.68 to $34.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
The securities are held of record by Mary Z. Luo. The reporting persons are husband and wife.
The shares are held of record by Applied Physics & Chemistry Laboratories, Inc., of which the reporting persons and The Bill Luobei Zhang 2004 Irrevocable Trust are the sole owners.
The shares are held of record in an account for the benefit of the reporting persons' son. The reporting persons disclaim beneficial ownership of these shares, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16, or for any other purpose.